Immuno-Competent 3D Tumour Models to Predict Patient Response
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (30 June 2022) | Viewed by 578
Special Issue Editors
Interests: 3D in vitro cancer models; tumouroids; targeted treatments; theranostics; nanotechnology; precision oncology; patient-derived 3D models
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Developing predictive models in the laboratory for personalised cancer treatment remains the major current challenge in oncology. 3D in vitro models which recapitulate key elements of solid tumours, such as topology, heterogeneity, and microenvironmental cues, have emerged as a realistic platform for investigations into the development and evaluation of new anti-cancer therapies.
Current research focuses on creating such models using patient derived cells and tissues and, importantly, in their incorporation into immunocomponent models to interrogate promising immunotherapies.
This Special Issue will present advances in the field of immunocompetent 3D models to predict patient response.
Prof. Marilena Loizidou
Prof. Miriam Dwek
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- organoids
- tissue-engineered tumouroids
- cancer-on-a chip
- patient-derived xenografts
- microfluidics
- 3D bioprinting
- T-cells
- tumour microenvironment
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
